La cadena de opciones muestra datos clave de las opciones de acciones de Tilray Brands a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Tilray Brands..

Tilray Brands (NASDAQ:TLRY) Bolsa, Cadena de Opciones

Tilray Brands

Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AMPG

AVGR

BIPC

CHEK

CREV

FDSB

HSDT

KORE

LAES

LIND

NCRA

NEUE

NVNI

RELI

SLGL

TIVC

TLRY

TOVX

Carbon Revolution lidera con un aumento del 62,4% en el premercado. ¿Qué otras acciones destacaron antes de la apertura?

Las acciones de Carbon Revolution (CREV) están subiendo un 62%; 20 acciones que se están moviendo en el premercado

Tilray Brands Inc

<a href="https://www.marijuanamoment.net/trump-white-house-invites-proposal-on-federal-marijuana-legalization-activist-says/" title="https://www.marijuanamoment.net/trump-white-house-invites-proposal-on-federal-marijuana-legalization-activist-says/">https://www.marijuanamoment.net/trump-white-house-invites-proposal-on-federal-marijuana-legalization-activist-says/</a>

Cannabis

AAWH

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

AUSAF

AVTBF

AYRWF

BBRRF

BHHKF

BLOZF

BMMJ

CANN

CBDY

CBMJ

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CHOOF

CLSH

CLVR

CNBS

CNBX

CNGGF

CNPOF

CNTMF

CNVCF

CPHRF

CRLBF

CRON

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CVHIF

CVSI

CWBHF

CANNIBIS GROWTH OPTY CORP by Cannabis Growth Opportunity Corp.

CWWBF

CXXIF

ELLXF

EMOR

ETST

EVIO

FFLWF

FFNTF

FUTURE FARM TECHNOLOGIES by Future Farm Technologies Inc.

FFRMF

FLGC

FLOOF

FLWPF

FINCANNA CAPITAL CORP by Fincanna Capital Corp.

FNNZF

FUAPF

GABRIELLAS KITCHEN INC by Gabriella's Kitchen Inc.

GABLF

GBHPF

GENE

GHBWF

GLASF

GNLN

GRAMF

GRNH

GRWG

GREEN SPIRIT INDUSTRIES by Green Spirit Industries Inc.

GSRX

GTBIF

HBOSF

HEMP

HERTF

HHPHF

HMLSF

IIPR

INCR

INLB

ISODIOL INTERNATIONAL ORD by Isodiol International Inc.

ISOLF

ITHUF

IVITF

JWCAF

KALY

KAYS

KHIRON LIFE SCIENCES CORP by Khiron Life Sciences Corp.

KHRNF

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LFCOF

LFLY

LIFD

LMLLF

LNLHF

LOVFF

LRSNF

LVRLF

LXLLF

MAPS

MGCLF

MGWFF

MJNE

MJUS

MMNFF

MPXOF

MRMD

NDVAF

NOBDF

NWVCF

OILFF

PHOT

PKPH

Watching Cannabis Stocks; Marijuana Moment Reports 'Trump White House Invites Proposal On Federal Marijuana Legalization, Activist Says'

Germany&#8217;s medical cannabis imports hit a record 31.6 metric tons in the fourth quarter of 2024, marking a nearly fourfold increase from Q1 2024 and a 53% rise from Q3 2024, according to a new report from Zuanic &amp; Associates. The surge is primarily attributed to changes in Germany&#8217;s Narcotics Law, implemented on April 1, 2024, which facilitated greater access to medical cannabis.
&#8220;Changes in the Narcotics Law&#8230;explain the jump in demand,&#8221; the report states, emphasizing how the revised regulations spurred higher import volumes.
<h2 class="wp-block-heading">Canada And Portugal Lead, But Competition Heats Up</h2>
Germany&#8217;s booming demand was met primarily by Canada and Portugal, which accounted for most of the absolute import growth between Q3 and Q4 2024. Canada remained the dominant supplier, responsible for 43% of imports in Q4, while Portugal secured 29% of the market.
Also read: <a href="https://www.benzinga.com/markets/cannabis/25/02/43757049/switzerland-moves-to-legalize-recreational-cannabis-under-strict-government-control">Switzerland Moves To Legalize Recreational Cannabis Under Strict Government Control</a>
Despite Canada&#8217;s lead, its market share declined significantly over the year. &#8220;The drop in Canadian share in 2H is notable,&#8221; Zuanic &amp; Associates reported, pointing to a fall from 57% in Q1 2024 to just 43% in Q4. Portugal, on the other hand, nearly doubled its stake from 13% in 2023 to 29% by the end of 2024, fueled by both domestic cultivation and EU-GMP-certified imports from Canada.
Denmark followed as the third-largest supplier, with 10% of Germany&#8217;s imports in Q4, while North Macedonia and Uruguay each accounted for 3%. Australia, South Africa and Spain held smaller shares.
<h2 class="wp-block-heading">Impact On Global Cannabis Markets</h2>
Germany&#8217;s surging demand is driving up cannabis prices internationally, particularly in Canada's B2B sector and in other export markets such as Australia. This trend benefits licensed producers with strong international operations or those looking to expand their footprint in Europe.
&#8220;German demand growth has also had a ripple effect pushing up Canadian B2B domestic prices, as well as prices to other export markets such as Australia,&#8221; the report notes.
<h2 class="wp-block-heading">Is Germany's Market Reaching Full Potential?</h2>
While Germany&#8217;s import numbers have skyrocketed, its medical cannabis penetration remains low compared to Canada and key U.S. states. According to the report, medical marijuana penetration in Germany is less than a third of Canada's (under 1% of the population) and well below Florida and Pennsylvania's 3% range.
Germany&#8217;s market is also fundamentally different from those in North America due to its pharmaceutical-focused framework. Patients must receive prescriptions detailing exact strains, dosages, and brands, with limited flexibility for pharmacies.
Growth potential remains high and experts predict an increase in telehealth prescriptions and online pharmacy accessibility, which could further expand the patient base.
<h2 class="wp-block-heading">Regulatory Stability Encourages Investment</h2>
Despite Germany&#8217;s shifting political landscape, no major regulatory changes are expected under the new government, according to Zuanic &amp; Associates. &#8220;No, we do not expect major changes in Germany's MMJ regulations under the new government (something to monitor),&#8221; the report states.
With pharmacy purchases estimated at 16-19 tons in Q4 2024, and annualized retail sales projected around €600 million ($640 million), the German medical cannabis market continues to establish itself as a key global player. Companies with established operations in Germany, including Tilray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>), Aurora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>), Canopy Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) and Curaleaf (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>), stand to benefit as the sector matures.
As demand keeps climbing and import sources diversify, Germany's position as Europe's cannabis powerhouse appears increasingly secure.
Read next: <a href="https://www.benzinga.com/markets/cannabis/25/02/43700972/how-a-german-vape-company-revolutionized-cannabis-consumption-forever-the-inside-story-of-storz-bickel">How A German Vape Company Revolutionized Cannabis Consumption Forever: The Inside Story Of Storz &amp; Bickel</a>

Analyst Color

Eurozone

Germany's Cannabis Imports Increase 4x In 2024 Amid Regulatory Changes: Which Countries Are Top Providers?

<a href="https://www.marijuanamoment.net/senator-john-fetterman-circulates-petition-to-legalize-marijuana-at-the-federal-level/" title="https://www.marijuanamoment.net/senator-john-fetterman-circulates-petition-to-legalize-marijuana-at-the-federal-level/">https://www.marijuanamoment.net/senator-john-fetterman-circulates-petition-to-legalize-marijuana-at-the-federal-level/</a>

Biotech

Politics

General

AKAN

IMCC

MSOS

SNDL

'Senator John Fetterman Circulates Petition To Legalize Marijuana At The Federal Level' - Marijuana Moment

Tilray Brands's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NYSE">TLRY</a>) short percent of float has fallen 8.45% since its last report. The company recently reported that it has 122.61 million shares sold short, which is 13.21% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.92 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Tilray Brands Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739900723_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tilray Brands has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Tilray Brands's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Tilray Brands's peer group average for short interest as a percentage of float is 12.47%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Tilray Brands's Recent Short Interest

It's been a whirlwind of a week in cannabis. Robert F. Kennedy Jr.&#8217;s confirmation as the new Secretary of Health and Human Services left the industry wondering what his renewed pledge to &#8220;follow the science on the harms of marijuana&#8221; might mean for broader legalization efforts. Meanwhile, on the other side of the aisle, President Donald Trump tapped Terrance Cole—a long-time &#8220;Just Say No&#8221; proponent—to lead the DEA, sending mixed signals after Trump's previous campaign promises.
In an unexpected twist, Trump's team also secured the release of U.S. citizen Marc Fogel from a Russian prison colony, where he'd been held for having medical marijuana. The industry witnessed both cautious optimism and fresh uncertainty as new appointments, policy shifts and high-profile business moves clashed and combined, shaping the future of legal cannabis in America and beyond.
<h2 class="wp-block-heading">Politics And Policy</h2>
Robert F. Kennedy Jr. Confirmed As HHS Secretary
The Senate confirmed Robert F. Kennedy Jr. to head the Department of Health and Human Services (HHS) in a narrow 52-48 vote, with Sen. Mitch McConnell as the sole Republican "no." Kennedy previously touted marijuana legalization on the 2023 campaign trail as a means to address "America's drug addiction problem." In a November 2023 interview, he suggested legal weed could help curtail opioid use.
Now, some cannabis advocates are alarmed by his pledge to "follow the science on the harms of marijuana." He also indicated that, in his new role, he would yield to the DEA's judgment on any rescheduling efforts. When told Sen. Pete Ricketts was concerned about "preventing the expansion of marijuana," Kennedy reportedly responded that he would stay true to evidence-based assessments.
Emily Paxhia of Poseidon Investment Management viewed Kennedy's appointment as a sign of shifting public sentiment around health: "RFK being confirmed demonstrates that the American perspective on ‘health' is shifting to a less conventional and more exploratory mindset. Cannabis sits squarely in the middle of this shift in the health zeitgeist."
Jeremy Berke of Cultivated Daily took a broader view, noting how President Donald Trump had likewise seemed pro-reform on the campaign trail, only to cool off on cannabis legalization once in office: "Trump posted in favor of cannabis reform on the campaign trail, but has been quiet ever since. It doesn&#8217;t appear to be an issue he wants to expend political capital on within his own party, but we can only hope we&#8217;re wrong."
For further details, <a href="https://www.benzinga.com/general/health-care/25/02/43708331/robert-f-kennedys-confirmation-cannabis-advocates-question-his-new-vow-to-follow-the-science-on-marijuanas-harms">read the full article</a>.
Trump Names Longtime &#8216;Just Say No&#8217; Champion As DEA Chief
Over at the White House, Trump tapped Terrance Cole, a 22-year DEA veteran, to serve as the agency's new leader. Cole is known for promoting a tough stance on cannabis, often echoing slogans from the 1980s war on drugs. His selection dimmed hopes that a Biden-era rescheduling push could make a comeback.
Trump announced Cole's appointment on social media, writing, "Together, we will save lives, and MAKE AMERICA SAFE AGAIN." The pick sent shockwaves through the cannabis industry, already uncertain about whether Trump would maintain—or roll back—federal cannabis reform.
<a href="https://www.benzinga.com/markets/cannabis/25/02/43667362/trump-appoints-anti-cannabis-just-say-no-drug-warrior-as-dea-chief">See the full article here</a>.
Trump Secures Release Of Cannabis Prisoner Marc Fogel
The Trump administration worked out an agreement with Russian authorities to bring Marc Fogel home after he'd served time in a Russian penal colony on cannabis charges. According to White House national security adviser Michael Waltz, Steve Witkoff, Trump's special envoy to the Middle East, personally traveled to Moscow to pick up Fogel.
"President Trump, Steve Witkoff and the president's advisors negotiated an exchange that serves as a show of good faith from the Russians and a sign we are moving in the right direction to end the brutal and terrible war in Ukraine," read Waltz's statement. Fogel's family thanked the administration, calling it "unwavering leadership" that finally ended his three-year ordeal.
Catch the story <a href="https://www.benzinga.com/news/global/25/02/43643471/trump-administration-secures-release-of-cannabis-prisoner-marc-fogel-from-14-year-russian-sentence">in full here</a>.
Local Developments: Michigan, Delaware And Argentina
Michigan: Governor Gretchen Whitmer proposed a $3 billion investment in road infrastructure, funded partly by a new wholesale cannabis tax. The plan—dubbed the Mi Road Ahead Plan—faces pushback from the local Chamber of Commerce, which fears higher tax burdens for businesses, while some lawmakers argue the state already collects enough for repairs.
Delaware: The state's adult-use market rollout continues, following newly finalized regulations for cultivating, processing and selling marijuana. More than 1,200 applications poured in, though only 125 licenses will be granted. Background checks are now underway and conditional licensees will have 18 months to become fully operational.
Argentina: Security Minister Patricia Bullrich vowed to overhaul the national registry for cannabis cultivation, citing concerns about potential abuse. She plans to reset the entire system, warning that "hecha la ley, hecha la trampa"—or, in essence, where there's a law, there's a loophole.
<h2 class="wp-block-heading">Markets And Business</h2>
Ispire Technology Posts Q2 Results
Ispire Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPR#NASDAQ">ISPR</a>) reported fiscal second-quarter 2025 revenue of $41.8 million, edging slightly higher from $41.7 million a year ago. Gross profit jumped to $7.7 million, a 23.5% increase, while net loss widened to $8 million. Co-CEO Michael Wang highlighted strategic gains, including an overseas expansion and a "successful pre-PMTA meeting with the FDA." CFO Jim McCormick emphasized plans to "reduce operating expenses by an anticipated $8 million annually" by shifting certain roles to Malaysia.
Chicago Atlantic BDC Secures $100M Credit Facility
Chicago Atlantic BDC, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIEN#NASDAQ">LIEN</a>), a specialty finance company primarily focused on the U.S. cannabis market, closed on a $100 million senior secured revolving credit facility led by an FDIC-insured bank. This additional capital will help fund new loans to cannabis operators. Executive chairman Scott Gordon noted the facility provides "significant liquidity" to support an active lending pipeline.
Green Check Teams Up With Plaid
Green Check, a key fintech player in cannabis banking, announced a partnership with Plaid, a data network known for secure digital financial services. The move allows underwriters on the Green Check platform to tap into Plaid's expansive network, improving due diligence for cannabis-related businesses. "Our platform has always been a foundation of financial services for the cannabis industry," said Bob Craig, EVP of strategic business development at Green Check. He added that Plaid's connectivity could further open up underbanked cannabis ventures to mainstream financial offerings.
Triple 5 Introduces &#8216;Pocket Dab&#8216;
House of brands Triple 5 released its Pocket Dab, a device that dispenses .1-gram live rosin "with each twist" for straightforward dosing. Inventor Mark Rhodes said, "We built the Pocket Dab to change the game," focusing on ease of use for both connoisseurs and newcomers. The device officially debuted at CHAMPS Vegas, featuring a sleek design, glass chamber and a black ceramic dual-coil system aimed at delivering "fresh, precise dabs without the mess."
"The Pocket Dab reflects Triple 5's mission to lead with innovation and deliver quality that retailers and consumers can trust," added Eli Dadon, CEO of Triple 5.
<h2 class="wp-block-heading">Innovation And Science</h2>
FDA Greenlights Fast-Track Cannabis Withdrawal Medication
Pharmaceutical upstart PleoPharma revealed that the U.S. Food and Drug Administration granted a fast-track designation for PP-01, its investigational treatment for cannabis withdrawal syndrome in patients with cannabis use disorder. If approved, PP-01 would be the first drug specifically formulated to address withdrawal symptoms—such as irritability, anxiety and insomnia—without relying on opioids. CEO Ginger Constantine said the medication's Phase 2b trial showed promise by reducing withdrawal's intensity and improving patient outcomes. A Phase 3 trial is next on the agenda.
<h2 class="wp-block-heading">Cultivation And Environment</h2>
Report: Indoor Growing Consumes More Energy Than All Outdoor Agriculture Combined
A study cited by Evan Mills of the Energy and Resources Group at UC Berkeley found that indoor cannabis cultivation in the U.S. uses more electricity than the entirety of outdoor agriculture. For perspective, according to Mills, some cannabis "plant factories" can draw up to 100 times more energy per square foot than a Walmart. The cause? Specialized, power-hungry lighting and climate-control systems—amplified by states that require in-state production. Despite the cannabis industry's rapid expansion, policymakers have only just begun grappling with its carbon footprint.
<h2 class="wp-block-heading">Global Developments</h2>
Australia's Medical Cannabis Market On The Rise
A new Prohibition Partners report highlights how Australia's medical cannabis market could soon outpace some of Europe's largest. The country's domestic production increased 6.7% in 2023 to 26.6 metric tons, though imports—especially from Canada—still dominate, hitting 42.1 tons in the same year. Local producers are concerned about low-cost Canadian cannabis driving down prices. Political momentum for adult-use legalization remains an open question: The Greens introduced a bill in 2023, but it ran into pushback from lawmakers citing health risks.
Tilray Continues German Expansion
Tilray Medical, a division of Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>), launched expanded medical cannabis extracts in Germany, emphasizing balanced THC-to-CBD ratios to meet patient demand. The new line includes higher-potency 1:1 formulations and smaller trial-size products. Denise Faltischek, chief strategy officer and head of international, calls the effort part of Tilray's "unwavering focus on innovation and education," underscoring Germany's continued importance as a core European market.
<h2 class="wp-block-heading">Events</h2>
Women Grow Leadership Summit 2025
Set to take place February 17-18 at the Gaylord National Resort in Maryland, the Women Grow summit promises deep dives on everything from business growth to policy advocacy. Brittney Griner, the three-time Olympic gold medalist, headlines with a keynote on women's empowerment, while NFL icon Ricky Williams will host a cannabis advocacy fundraiser. Founder Dr. Chanda Macias sees the summit as both a career fair and a platform to forge serious deals for up-and-coming entrepreneurs: "We will shape the future of cannabis and empower women across the globe."
<h2 class="wp-block-heading">What We&#8217;re Reading</h2>
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/25/02/43700972/how-a-german-vape-company-revolutionized-cannabis-consumption-forever-the-inside-story-of-storz-bickel">How A German Vape Company Revolutionized Cannabis Consumption Forever: The Inside Story Of Storz &amp; Bickel</a></li>
<li><a href="https://www.benzinga.com/general/health-care/25/02/43666635/zyn-changed-nicotine-forever-are-cannabis-pouches-the-next-big-thing">Zyn Changed Nicotine Forever &#8211; Are Cannabis Pouches The Next Big Thing?</a></li>
<li><a href="https://www.benzinga.com/news/retail-sales/25/02/43605950/inside-the-first-black-and-latina-owned-vertically-integrated-cannabis-company-in-the-us">Inside The First Black And Latina-Owned Vertically Integrated Cannabis Company In The US</a></li>
<li><a href="https://www.forbes.com/sites/javierhasse/2025/02/13/rap-battles-are-now-big-business-billions-of-views-millions-in-profits-and-cannabis-wants-in/">Rap Battles Are Now Big Business: Billions Of Views, Millions In Profits—And Cannabis Wants In</a></li>
</ul>

Earnings

Government

Latin America

ISPR

LIEN

This Week In Cannabis: RFK's HHS Confirmation, Trump's DEA Bombshell, Earnings, Global News And More

Tilray Medical Announce The Expansion Of Its Industry-leading Medical Cannabis Extract Portfolio In Germany

<a href="https://themarijuanaherald.com/2025/02/dea-official-says-marijuana-rescheduling-is-delayed-but-certainly-not-dead/" title="https://themarijuanaherald.com/2025/02/dea-official-says-marijuana-rescheduling-is-delayed-but-certainly-not-dead/">https://themarijuanaherald.com/2025/02/dea-official-says-marijuana-rescheduling-is-delayed-but-certainly-not-dead/</a>

Legal

"DEA Official Says Marijuana Rescheduling Is 'Delayed, But Certainly Not Dead'" - The Marijuana Herald

Tilray's primary Canadian production facilities, Aphria One and Aphria Diamond, are now fully planted and positioned to capture the growing demand from Canadian and International cannabis markets. Certain sections of Aphria One, which were previously idled during the COVID-19 pandemic, are now back online.

Tilray Brands Completed Phase 1 Of Its Accelerated Growth Plan For Its Cannabis Supply Chain, Which Began With Increased Planting In Late 2024, Phase 2 Of The Growth Plan Includes Planting The Outdoor Cultivation Site In Cayuga This Spring

On Feb 5, Tilray Brands  Settled Aphria Canadian Class Action; Aphria Canadian Class Action Settlement Amount Agreed At C$30 Million

From political maneuvering in Washington to major corporate developments across the global cannabis landscape, this week has been packed with pivotal moments for the industry. In the U.S., Florida Governor Ron DeSantis is doubling down on his opposition to recreational cannabis, predicting that a renewed 2026 ballot initiative will face &#8220;big-time trouble.&#8221;
On the business side, Village Farms International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) officially launched sales in the Netherlands, marking a significant milestone for Europe&#8217;s evolving cannabis market. In Canada, Aurora Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) reported a <a href="https://www.benzinga.com/markets/cannabis/25/02/43498531/why-aurora-cannabis-stock-is-skyrocketing-today-what-about-canopy-tilray-and-cronos">record-breaking quarter</a> with soaring international sales, while Canopy Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) managed to <a href="https://www.benzinga.com/general/health-care/25/02/43562398/why-is-canada-based-cannabis-firm-canopy-growth-stock-trading-lower-on-friday">exceed revenue expectations</a> despite ongoing struggles in the consumer sector.
In New York, a <a href="https://www.benzinga.com/markets/cannabis/25/02/43541317/inside-new-yorks-bold-plan-to-decriminalize-drug-possession">new bill aims to decriminalize all drug possession</a>, a move that could reshape the state&#8217;s approach to substance use. Meanwhile, Chile is facing political controversy as lawmaker and cannabis advocate <a href="https://www.benzinga.com/25/02/43561786/why-this-lawmaker-refuses-to-take-a-mandatory-drug-test-drama-in-the-chilean-congress">Ana María Gazmuri</a> challenges the country's mandatory drug testing policy for public officials.
On the lifestyle front, Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) continues expanding into the craft beer market with a <a href="https://www.benzinga.com/markets/cannabis/25/02/43537012/cannabis-giant-tilray-doubles-down-on-its-beer-business-with-new-jetblue-partnership">high-profile partnership</a> placing Montauk Brewing beers on JetBlue (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) flights. And in an industry-first, New York cannabis retailer The Travel Agency has secured ad space in Playbill, bringing legal cannabis into Broadway's mainstream culture.
Now, let&#8217;s break down the biggest stories of the week.
<h2 class="wp-block-heading">In Today&#8217;s Issue Of &#8216;The Week In Cannabis&#8217;</h2>
Politics &amp; Policy
<ul>
<li>DeSantis: Florida Legalization Faces ‘Big-Time Trouble' in 2026</li>
<li>New York Bill Proposes Full Drug Decriminalization</li>
</ul>
Market &amp; Business Developments
<ul>
<li>Village Farms Begins Legal Cannabis Sales in the Netherlands</li>
<li>Aurora Cannabis Reports Record Medical Sales Growth</li>
<li>Canopy Growth Beats Revenue Expectations Despite Challenges</li>
<li>iAnthus Sells Arizona Assets for $36.5M to Sonoran Roots</li>
<li>Tilray Expands Craft Beer Reach with JetBlue Partnership</li>
</ul>
Culture &amp; Regulation
<ul>
<li>Chilean Lawmaker Fights Mandatory Drug Testing for Officials</li>
<li>Panama Approves Hemp Law After Years of Delays</li>
<li>New York's Cannabis Scene Breaks into Broadway</li>
</ul>
Industry Trends &amp; Market Analysis
<ul>
<li>US Cannabis Growth Slows, Business Failures Rise</li>
<li>Elon Musk Pushes Drug Testing for Federal Employees</li>
</ul>
<h2 class="wp-block-heading">Politics And Policy: Reform In The Spotlight</h2>
<h4 class="wp-block-heading">DeSantis: Florida Legalization Faces ‘Big-Time Trouble' in 2026</h4>
Florida Governor Ron DeSantis has already set his sights on stopping a new recreational cannabis ballot initiative for 2026, after the 2024 measure failed to reach the 60% approval needed. He warned that the initiative will struggle to make it onto the ballot, citing expected legal challenges from the Florida Supreme Court.
Comparing cannabis policy to &#8220;pregnant pig care in the U.S. Constitution,&#8221; DeSantis argued that legalization should be left to lawmakers, not voter referendums. Meanwhile, Florida's medical cannabis industry remains one of the nation's most profitable, making the state a key battleground for reform.
<h4 class="wp-block-heading">New York Bill Proposes Full Drug Decriminalization</h4>
New York lawmakers introduced Senate Bill S3600, aiming to eliminate criminal and civil penalties for personal drug possession, shifting policy toward public health. Sponsored by State Senator Gustavo Rivera, the bill would expunge past convictions, prevent penalties for parolees, and replace arrests with fines or treatment referrals.
The proposal follows global models in Portugal and Oregon that have reduced overdoses and incarceration. Critics warn that New York must expand treatment access before decriminalization, but supporters argue it's a necessary step to end ineffective drug criminalization.
<h2 class="wp-block-heading">Market And Business Developments: Expansion, Earnings And Deals</h2>
<h4 class="wp-block-heading">Village Farms Begins Legal Cannabis Sales In The Netherlands</h4>
Village Farms International has officially launched cannabis sales in the Netherlands through its wholly owned subsidiary, Leli Holland. The company completed its first harvest in December and will begin supplying Dutch coffeeshops on February 7.
Leli Holland is one of 10 licensed producers in the country's regulated recreational cannabis program. Village Farms CEO Michael DeGiglio called the Dutch market &#8220;one of the most attractive cannabis investment opportunities globally,&#8221; citing strong demand, a favorable pricing environment, and a zero-tax policy on regulated products. Full-scale operations are expected by Q2 2025.
<h4 class="wp-block-heading">Aurora Cannabis Reports Record Medical Sales Growth</h4>
Aurora Cannabis posted a 37% revenue increase in Q3 2025, reaching CA$88.2 million, with its global medical cannabis business growing 51%. CEO Miguel Martin highlighted all-time highs in medical sales, net income and free cash flow.
International medical cannabis sales surged in markets like Australia, Germany, Poland and the UK, helping offset a 15% decline in consumer cannabis revenue. The company also saw a 22% increase in plant propagation revenue. Aurora expects further growth next quarter, driven by international expansion and seasonal demand for plant propagation.
<h4 class="wp-block-heading">Canopy Growth Beats Revenue Expectations Despite Challenges</h4>
Canopy Growth reported Q3 sales of CA$74.76 million, surpassing analyst expectations but reflecting an overall decline from the previous year. Growth in Canada's medical cannabis and international markets offset weaker performance in the consumer sector.
CEO Luc Mongeau pointed to strong medical cannabis sales, Storz &amp; Bickel vaporizer revenue and the launch of Claybourne-infused pre-rolls in Canada as key drivers. Adjusted EBITDA improved significantly year-over-year, but challenges remain as the company navigates shifting consumer demand.
<h4 class="wp-block-heading">iAnthus Sells Arizona Assets For $36.5M To Sonoran Roots</h4>
iAnthus Capital Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) is selling three dispensaries and two processing facilities in Arizona to Sonoran Roots for $36.5 million. The deal includes $20 million in cash and a $16.5 million secured promissory note.
The move aligns with iAnthus' strategy to focus on key markets like Florida, Maryland, New Jersey and New York. CEO Richard Proud said the sale will help the company &#8220;double down on markets where we can deliver the most value to our customers.&#8221; iAnthus will maintain one dispensary in Mesa and continue selling its MPX brand in Arizona.
<h4 class="wp-block-heading">Tilray Expands Craft Beer Reach with JetBlue Partnership</h4>
Tilray Brands continues its push into the alcohol market with a new partnership placing Montauk Brewing's Surf Beer Golden Ale on all JetBlue flights. The deal marks the first time JetBlue will serve Montauk's flagship beer, giving the cannabis company greater exposure in mainstream beverage distribution.
Tilray has aggressively expanded its beer portfolio through acquisitions of brands like SweetWater, Blue Point and Shock Top. While cannabis remains its core business, CEO Irwin Simon has positioned Tilray's beverage division as a strategic bridge for future cannabis-infused drinks once regulations allow.
<h2 class="wp-block-heading">Culture And Regulation: Cannabis In Society And Policy Shifts</h2>
<h4 class="wp-block-heading">Chilean Lawmaker Fights Mandatory Drug Testing for Officials</h4>
A political storm erupted in Chile's Congress after lawmaker and longtime cannabis advocate Ana María Gazmuri refused to comply with mandatory biannual drug testing for public officials. As a result, she was penalized with a 15% salary reduction, but she remains defiant, calling the policy &#8220;poorly designed, lacking transparency, and infringing on fundamental rights.&#8221;
Gazmuri, a medical cannabis user with a legal prescription, also disclosed her guided use of psilocybin mushrooms but emphasized that her refusal to take the test was about principle, not personal drug use. She argued that if the real goal is uncovering ties between politicians and drug trafficking, financial investigations should take priority.
Right-wing lawmakers have responded by proposing a constitutional amendment that would remove any public official who consumes illegal substances. Gazmuri, however, remains firm in her stance, vowing to continue pushing for broader drug policy reform.
<h4 class="wp-block-heading">Panama Approves Hemp Law After Years Of Delays</h4>
Panama's long-awaited hemp regulation finally passed after years of bureaucratic delays, clearing the way for industrial hemp production, commercialization and export. The legislation had been stalled under the previous administration but gained momentum with new lawmakers and business sector support.
Advocates argue the new hemp industry could create jobs, attract investment and even help alleviate Panama's struggling social security system. However, the fate of the law now rests with President José Raúl Mulino, who has yet to sign it. If approved, Panama could position itself as a leader in the regional hemp market.
<h4 class="wp-block-heading">New York's Cannabis Scene Breaks Into Broadway</h4>
New York cannabis retailer The Travel Agency has made history as the first marijuana business to advertise in Playbill, the iconic magazine of Broadway theater goers. The campaign, which promotes cannabis as a way to &#8220;Experience a Matinee for Your Mind,&#8221; coincides with the company opening a third retail store near Radio City Music Hall.
The Travel Agency has also partnered with Broadway productions like An Axemas Story and launched an online guide featuring cannabis products tailored for theater lovers. Industry insiders see this as a major step in normalizing cannabis within mainstream cultural spaces.
<h2 class="wp-block-heading">Industry Trends And Market Analysis: Growth, Struggles And The Road Ahead</h2>
<h4 class="wp-block-heading">US Cannabis Growth Slows, Business Failures Rise</h4>
Despite posting its 11th consecutive year of revenue growth, the US legal cannabis industry saw its expansion slow in 2024, with sales increasing just 6% to around $30.5 billion, according to Whitney Economics.
The number of struggling businesses is rising, with nearly 1,000 fewer active cannabis licenses by year's end. A staggering 72.7% of operators reported being unprofitable, with many blaming federal inaction on banking, tax reform, and interstate commerce.
Michigan was a rare bright spot, hitting $3.3 billion in sales, partially fueled by out-of-state buyers. New York also exceeded expectations after regulatory changes, while Florida underperformed due to a slowdown in medical patient registrations. Meanwhile, mature markets like Colorado, Oregon, and Washington saw demand flatten or decline.
Whitney Economics warns that without major policy changes, business failures will continue accelerating in 2025.
<h4 class="wp-block-heading">Elon Musk Pushes Drug Testing For Federal Employees</h4>
Elon Musk has thrown his support behind a proposal for mandatory, immediate drug testing across the federal workforce, a move that aligns with his broader push to shrink government operations.
The idea, first floated by former National Security Council official Joshua Steinman, was met with Musk's simple endorsement: &#8220;Great idea.&#8220; While federal employees in certain positions already undergo drug screenings, Musk's proposal could drastically expand testing.
Ironically, Musk himself was subjected to random drug tests for a year after smoking cannabis on Joe Rogan's podcast in 2018. He has since spoken openly about using ketamine for depression and has supported psychedelics research.
His latest stance comes as Senator Elizabeth Warren has urged Musk to cut &#8220;wasteful&#8220; spending on cannabis enforcement, a move that could save hundreds of millions annually. Whether Musk will act on that remains to be seen.

JBLU

This Week In Cannabis: DeSantis' Anti-Weed Push, NY's Drug Decriminalization, Aurora's Record Earnings, Tilray And More Global News

Tilray Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) is deepening its bet on the beverage alcohol sector, this time through a high-profile partnership with JetBlue Airways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>). The collaboration, announced earlier this week, places Montauk Brewing Company&#8217;s Surf Beer Golden Ale on all domestic and international JetBlue flights, marking a major step in Tilray's mainstream beer distribution strategy.
JetBlue passengers can now enjoy Montauk&#8217;s easy-drinking golden ale while cruising at 30,000 feet, a move that further integrates Tilray's growing craft beer empire into everyday consumer experiences. The airline is the first to feature Montauk's beer, offering travelers a sip of the brand's signature coastal lifestyle.
&#8220;We are proud and excited that JetBlue selected our Montauk Surf Beer Golden Ale to offer to travelers worldwide,&#8221; said Montauk Brewing co-founder Vaughan Cutillo. &#8220;This selection represents not just a beverage but the embodiment of relaxation and joy that Montauk Brewing stands for. We hope that every sip taken at 30,000 feet connects our consumers to the carefree spirit of Montauk and the adventurous journey ahead.&#8221;
<h3 class="wp-block-heading">A Cannabis Company&#8217;s Expansion Into Craft Beer</h3>
While best known for its cannabis business, Tilray has aggressively expanded into the alcoholic beverage industry, establishing itself as a significant player in craft beer. Through strategic acquisitions of well-known brands, Tilray has built a diverse portfolio that includes Montauk Brewing, SweetWater Brewing, Breckenridge Brewery, Blue Point Brewing and several others.
In 2024 alone, Tilray acquired four craft breweries from Molson Coors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>), adding Hop Valley Brewing (Oregon), Terrapin Beer Co. (Georgia), Revolver Brewing (Texas) and Atwater Brewery (Michigan) to its roster. This followed a deal with Anheuser-Busch InBev (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUD#NYSE">BUD</a>) that saw Tilray take over eight beer brands, including Shock Top, Redhook Brewery and Widmer Brothers Brewing.
The JetBlue deal represents more than just an airline partnership, it signals Tilray's continued push into mainstream beverage distribution. By securing an inflight placement with a major U.S. airline, Tilray is further embedding its beer brands into everyday consumer interactions, mirroring strategies employed by major beverage conglomerates to drive visibility and sales.
<h3 class="wp-block-heading">Beer And Cannabis: Tilray's Long-Term Play</h3>
Tilray&#8217;s foray into alcohol is not just about immediate revenue, it&#8217;s a long-term strategy that could position the company advantageously for the future of cannabis-infused beverages. With cannabis still federally illegal in the U.S., Tilray has leveraged its beer acquisitions as a way to build brand familiarity, consumer trust, and distribution networks ahead of potential regulatory changes.
CEO Irwin Simon has previously spoken about the company's intent to dominate the cannabis lifestyle space, integrating cannabis with complementary sectors like alcohol and wellness. If cannabis-infused beverages eventually gain regulatory approval, Tilray would be well-positioned with its existing brewery network to capitalize on the opportunity.
<h3 class="wp-block-heading">A Win For JetBlue?</h3>
For JetBlue, the partnership aligns with its strategy of offering unique, high-quality inflight experiences. The airline has long prioritized differentiation through onboard perks, such as free Wi-Fi and generous legroom, and the addition of a well-regarded craft beer fits that mold. JetBlue has also been steadily enhancing its beverage offerings to cater to a younger, more experience-driven consumer base, making Montauk Brewing a natural fit.
With this latest move, Tilray continues to push its beverage division into high-visibility channels, further solidifying its commitment to alcohol as a key component of its business model. Whether this is a stepping stone to broader partnerships or a precursor to cannabis-infused beverages, one thing is clear—Tilray is betting big on beer.
Photo via Shutterstock

Cannabis Giant Tilray Doubles Down On Its Beer Business With New JetBlue Partnership

WIIM

Cannabis companies are trading higher amid Robert F. Kennedy Jr.'s nomination as HHS secretary and a Senate banking hearing pushing to ease regulations for legal cannabis businesses.

U.S. stocks were mostly lower, with the Nasdaq Composite falling around 100 points on Wednesday.
Shares of Electronic Arts Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) rose sharply during Wednesday's session after the company reported better-than-expected third-quarter EPS results. B of A Securities raised its price target on the stock <a href="https://www.benzinga.com/25/02/43492624/electronic-arts-sees-strong-q3-earnings-boosted-by-ea-sports-fc-success-25-billion-shareholder-return-plan">from $130 to $132</a>.
Electronic Arts posted net bookings of $2.215 billion and GAAP earnings of $1.11 per share, beating estimates of $1.07 per share.
Electronic Arts shares jumped 5.4% to $127.83 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>BigBear.ai Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) shares surged 33.99% to $6.58. BigBear.ai won Department of Defense contract to prototype near-peer adversary geopolitical risk analysis for Chief Digital and Artificial Intelligence Office.</li>
<li>Criteo SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRTO#NASDAQ">CRTO</a>) shares jumped 20% to $46.06 following better-than-expected fourth-quarter reported financial results and an increase in its share buyback authorization program.</li>
<li>Mercury Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRCY#NASDAQ">MRCY</a>) gained 19% to $49.68 after the company reported better-than-expected quarterly financial results.</li>
<li>Tilray Brands Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) gained 17% to $1.16.</li>
<li>SSR Mining Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSRM#NASDAQ">SSRM</a>) gained 16.8% to $9.57 after RBC Capital upgraded the stock from Underperform to Sector Perform and raised its price target from $5.5 to $8.</li>
<li>Mattel Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>) rose 12.7% to $20.37 following better-than-expected fourth-quarter financial results. Jefferies upgraded the stock from Hold to Buy following the report.</li>
<li>Embraer SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERJ#NYSE">ERJ</a>) gained 11.6% to $44.48 after its executive jets subsidiary announced a purchase agreement with Flexjet in which it secured a $7 billion order.</li>
<li>Johnson Controls International PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) gained 11.2% to $85.97 after the company reported better-than-expected first-quarter financial results and FY25 outlook. They also appointed Joakim Weidemanis as next CEO.</li>
<li>Mueller Water Products Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MWA#NYSE">MWA</a>) gained 10.8% to $25.60 following better-than-expected quarterly reported financial results. Additionally, the company raised its FY25 adjusted EBITDA guidance and issued FY25 revenue guidance above estimates.</li>
<li>Champion Homes Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKY#NYSE">SKY</a>) gained 9.5% to $101.61 after the company reported better-than-expected quarterly financial results.</li>
<li>Tempus AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) rose 8.7% to $67.21 after TD Cowen reinstated a Buy rating on the stock and announced a price target of $74.</li>
<li>Bloom Energy Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) gained 8.2% to $25.02.</li>
<li>GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) gained 7.8% to $37.52 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Fiserv Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) shares surged 7.1% to $229.37 following better-than-expected quarterly reported financial results.</li>
<li>Powell Industries Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) gained 5.8% to $246.82. Powell Industries raised its quarterly dividend to $0.2675 per share.</li>
<li>BioNTech SE – ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) rose 5.7% to $123.76.</li>
<li>Toyota Motor Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>) gained 3.8% to $194.68 after the company reported a year-over-year increase in third-quarter financial results and issued FY25 guidance above estimates.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43460681/jim-cramer-says-no-to-bigbear-ai-recommends-buying-this-tech-stock">Jim Cramer Says No To BigBear.ai, Recommends Buying This Tech Stock</a></li>
</ul>

Intraday Update

BBAI

BNTX

CRTO

Embraer-Empresa Brasileira De Aeronautica

MRCY

POWL

SSRM

Electronic Arts Posts Upbeat Earnings, Joins Mattel, Johnson Controls, Mueller Water Products And Other Big Stocks Moving Higher On Wednesday

Aurora Cannabis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) stock surged more than 45% on Wednesday morning following the release of its <a href="https://www.benzinga.com/news/earnings/25/02/43496003/aurora-cannabis-stock-jumps-on-record-breaking-q3-earnings">third-quarter fiscal 2025 earnings</a>, which revealed a substantial increase in revenue and profitability. The company reported total net revenue of CA$88.2 million ($61.74 million), up 37% year-over-year, driven largely by a 51% jump in its global medical cannabis business.
&#8220;This quarter was record-breaking for Aurora, driven by all-time highs in global medical net revenue, net income, adjusted EBITDA, and free cash flow,&#8221; said Miguel Martin, Aurora's executive chairman and CEO. The company also posted a net income of CA$31.2 million, a 282% year-over-year increase, and an adjusted EBITDA of CA$23.1 million, up 316%.
<h2 class="wp-block-heading">Cannabis Stocks Rally In Sympathy?</h2>
The strong earnings report triggered a broader rally in the cannabis sector, with several companies experiencing notable gains:
<ul>
<li>Canopy Growth Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) jumped over 23%.</li>
<li>Tilray Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) climbed more than 10%.</li>
<li>Cronos Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) rose approximately 8%.</li>
</ul>
Investors appear to be reacting positively to Aurora's performance, particularly its growing international medical cannabis revenues and improved profitability.
<h2 class="wp-block-heading">Do Trade Tensions Play A Role?</h2>
Beyond earnings, another factor likely contributing to the sector-wide rally is the 30-day delay in U.S.-Canada tariffs, a move that has eased investor concerns. The Trump administration postponed the imposition of 25% tariffs on Canadian imports, providing a window for further trade negotiations. While cannabis wasn't explicitly mentioned in the tariff discussions, the broader economic impact on trade between the countries may be influencing sentiment toward Canadian cannabis companies.
As Aurora continues to expand its medical cannabis footprint globally, investors are closely watching whether the company can sustain its momentum in upcoming quarters.
Illustration made with Canva.

Equities

Why Aurora Cannabis Stock Is Skyrocketing Wednesday: What About Canopy, Tilray, Cronos?

Macro Economic Events

Economics

MRNA

NVAX

Republican Senator Bill Cassidy Votes To Advance Nomination Of Robert F. Kennedy As U.S. HHS Secretary; U.S. Senate Finance Committee Votes 14-13 To Advance Kennedy Nomination Favorably

Tilray Brands' Sweetwater Brewing Launches Dive Beer

Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) stock is trading lower on Monday, alongside other cannabis-related stocks, following President Donald Trump's announcement of new tariffs on imported goods from Canada, Mexico and China, set to take effect Tuesday. Trump has since temporarily paused the 25% tariff on imports from Mexico <a href="https://www.benzinga.com/government/regulations/25/02/43440692/us-mexico-agrees-on-one-month-tariffs-pause-stocks-rebound-peso-rallies">for one month</a>.
The Details: The 25% <a href="https://www.benzinga.com/25/02/43434471/trumps-tariffs-hit-markets-natural-gas-spikes-mexican-peso-hits-2-year-lows-bitcoin-freefalls-the-outlook-is-unclear-analysts-warn">tariff on goods from Canada</a> and the additional 10% tariff on goods from China are still scheduled to go into effect on Tuesday. However, energy exports from Canada will face a lower tariff rate of 10%.
Tilray and other cannabis-related stocks may be falling as investors weigh the potential impact of tariffs on the sector. For instance, tariffs could drive up the cost of importing raw materials and other supplies. Additionally, increased trade tensions and economic uncertainty could be dampening investor sentiment.
Trump reportedly <a href="https://www.benzinga.com/trading-ideas/movers/25/02/43435750/ford-general-motors-shares-are-sliding-monday-whats-going-on">stated</a> that while Americans might feel "some short-term pain" from the tariffs, in the long run, the U.S. has been "ripped off by virtually every country."
Canadian Prime Minister Justin Trudeau <a href="https://www.benzinga.com/markets/25/02/43423087/canada-retaliates-against-trumps-tariffs-with-countermeasures-25-tariffs-on-107-billion-of-us-made-goods">responded</a> to Trump&#8217;s tariffs by implementing a 25% tariff on more than $100 billion worth of U.S. goods. Trudeau and Trump are set to discuss the tariffs over the phone later today.
Other cannabis-related stocks also moving lower following Trump's announcement include Aurora Cannabis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) and SNDL, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>).
Related Link: <a href="https://www.benzinga.com/25/02/43444304/ppg-industries-analysts-cut-their-forecasts-following-weak-q4-earnings">PPG Industries Analysts Cut Their Forecasts Following Weak Q4 Earnings</a>
TLRY Price Action: At the time of publication, Tilray shares are trading 5.10% lower at 99 cents, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Image: This illustration was generated using artificial intelligence via Midjourney.

What's Going On With Tilray Brands Stock Monday?

Shares of cannabis-linked stocks are trading lower as traders evaluate tariff risks.

Tilray Brands's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NYSE">TLRY</a>) short percent of float has risen 6.81% since its last report. The company recently reported that it has 133.89 million shares sold short, which is 14.43% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.98 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Tilray Brands Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738251018_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tilray Brands has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Tilray Brands's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Tilray Brands's peer group average for short interest as a percentage of float is 13.82%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Comments

Tilray Brands

Tilray Brands (TLRY) Opciones

Tilray Brands (NASDAQ:TLRY) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL